Browsing Tag
Ophthalmology
32 posts
Innovent Biologics advances Phase 2 study of efdamrofusp alfa in diabetic macular edema amid global push for longer-acting therapies
Innovent launches Phase 2 trial of its anti-VEGF-complement fusion protein IBI302 to rival Faricimab in treating diabetic macular edema.
Alcon’s Clareon Vivity IOL gains CE Mark approval, expanding vision correction options in Europe
Discover how Alcon’s Clareon Vivity IOL is transforming cataract surgery with CE Mark approval, offering presbyopia correction and extended vision clarity in Europe.
Cipla secures exclusive rights to market Formosa Pharmaceuticals’ APP13007 across 11 countries
Cipla Limited has expanded its presence in the ophthalmology market through a multi-regional licensing agreement with Formosa Pharmaceuticals,…
Diabetic retinopathy: How diabetes can lead to vision loss and what you can do about it
Diabetic retinopathy is a serious and potentially blinding complication of diabetes that affects the retina—the part of the…
Merck to acquire EyeBio in $3bn deal to expand ophthalmology pipeline
Merck (NYSE: MRK), also known as MSD outside of the United States and Canada, has announced a definitive…
Kodiak Sciences advances Phase 3 study of tarcocimab tedromer in diabetic retinopathy
Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company focused on developing transformative therapeutics for retinal diseases, announced that…
Sandoz to acquire biosimilar CIMERLI from Coherus BioSciences to expand ophthalmology portfolio
In a significant development within the pharmaceutical and healthcare industry, Sandoz, a global leader in generic and biosimilar…
ABBV-RGX-314 : REGENXBIO reports positive Phase 2 data on diabetic retinopathy gene therapy candidate
REGENXBIO Inc. has disclosed new findings from its Phase II ALTITUDE trial, focusing on ABBV-RGX-314 as a gene…
Bausch + Lomb completes XIIDRA acquisition to fortify dry eye offering
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a prominent global eye health company, has successfully wrapped up its acquisition…
OcuTerra Therapeutics moves forward with OTT166 eye drops in Phase 2 trial
OcuTerra Therapeutics, a clinical-stage ophthalmology company, announced the successful full enrollment in its Phase 2 DR:EAM (Diabetic Retinopathy:…